ConductScience.org, home

Paper39007759

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Hong CR and 11 others. J Med Chem, 2024. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers. Papers, record 39007759. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39007759

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.
PubMed
Journal
J Med Chem
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.4, provisional
iCite
Revised in PubMed
2025-09-02
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hong CRCho R
2Liew LPLydia P
3Wong WWWay W
4Dickson BDBenjamin Dhttps://orcid.org/0000-0001-6860-903X
5Cheng GGary
6Shome AAvik
7Airey RRebecca
8Jaiswal JJagdish
9Lipert BBarbara
10Jamieson SMFStephen M Fhttps://orcid.org/0000-0002-5485-9211
11Wilson WRWilliam R
12Hay MPMichael Phttps://orcid.org/0000-0002-7087-9087

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DNA-Activated Protein KinaseMajor topic
Protein Kinase InhibitorsMajor topic
Radiation-Sensitizing AgentsMajor topic
Humans
Animals
Structure-Activity Relationship
Mice
Cell Line, Tumor
Imidazoles
Pyridones
Xenograft Model Antitumor Assays
Mice, Nude
Rats

Source PubMed

Download CSV of topics

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135978693Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.ACS Med Chem Lett2022https://conductscience.org/library/papers/35978693PubMed
29510041
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
Radiother Oncol1998https://conductscience.org/library/papers/9510041PubMed
338426642Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.Mol Oncol2024https://conductscience.org/library/papers/38426642PubMed
418849971Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.Nat Chem Biol2008https://conductscience.org/library/papers/18849971PubMed
533077952Dimers of DNA-PK create a stage for DNA double-strand break repair.Nat Struct Mol Biol2021https://conductscience.org/library/papers/33077952PubMed
6199254303D-QSAR studies on a series of inhibitors docked into a new homology model of the DNA-PK receptor.Curr Pharm Des2009https://conductscience.org/library/papers/19925430PubMed
731490091Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.Int J Radiat Biol2019https://conductscience.org/library/papers/31490091PubMed
821606941Targeting hypoxia in cancer therapy.Nat Rev Cancer2011https://conductscience.org/library/papers/21606941PubMed
928652322Cryo-EM structure of the DNA-PK holoenzyme.Proc Natl Acad Sci U S A2017https://conductscience.org/library/papers/28652322PubMed
1032220971Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.Mol Cancer Ther2020https://conductscience.org/library/papers/32220971PubMed
1123636326mTOR kinase structure, mechanism and regulation.Nature2013https://conductscience.org/library/papers/23636326PubMed
1236471053Targeting DNA damage response pathways in cancer.Nat Rev Cancer2023https://conductscience.org/library/papers/36471053PubMed
132215662The scid mutation in mice causes a general defect in DNA repair.Nature1990https://conductscience.org/library/papers/2215662PubMed
1431541630Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.Biochem Pharmacol2019https://conductscience.org/library/papers/31541630PubMed
1521664823Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.Bioorg Med Chem2011https://conductscience.org/library/papers/21664823PubMed
1619133841Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining.Biochem J2009https://conductscience.org/library/papers/19133841PubMed
1734428039BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.J Med Chem2021https://conductscience.org/library/papers/34428039PubMed
1837298933Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.Molecules2023https://conductscience.org/library/papers/37298933PubMed
1923386830Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.Front Pharmacol2013https://conductscience.org/library/papers/23386830PubMed
2037351169DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.Theranostics2023https://conductscience.org/library/papers/37351169PubMed

See all 74 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42266865Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation.RSC Med Chem2026https://conductscience.org/library/papers/42266865PubMed
41427993Multi-scale in-silico modelling to unveil structural requirements for DNA-PK inhibitors as radiosensitizers and MolSHAP based design of novel ligands.J Comput Aided Mol Des2025https://conductscience.org/library/papers/41427993PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
PIK3CD5293PubTator's text mininghttps://conductscience.org/library/genes/5293NCBI Gene
PRKDC5591PubTator's text mininghttps://conductscience.org/library/genes/5591NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39007759

GET https://conductscience.org/api/papers/v1/39007759/references?page=2